Evidence map›Paper›PMID 35704393›Full record

ArticleLetters in applied microbiology2022

Evaluating the impact of ultraviolet C exposure conditions on coliphage MS2 inactivation on surfaces.

K Ratliff, L Oudejans, W Calfee, A Abdel-Hady, M Monge, D Aslett

Abstract read
In one paragraph

Article in Letters in applied microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

K RatliffCenter for Environmental Solutions and Emergency Response, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.ORCID https://orcid.org/0000-0003-1410-2756
L OudejansCenter for Environmental Solutions and Emergency Response, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.ORCID https://orcid.org/0000-0002-7594-4394
W CalfeeCenter for Environmental Solutions and Emergency Response, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.ORCID https://orcid.org/0000-0001-6544-329X
A Abdel-HadyJacobs Technology Inc., Research Triangle Park, NC, USA.ORCID https://orcid.org/0000-0002-4836-7210
M MongeConsolidated Safety Services, Inc., Research Triangle Park, NC, USA.
D AslettJacobs Technology Inc., Research Triangle Park, NC, USA.ORCID https://orcid.org/0000-0002-2500-0184

Funding

EPA 68HERC20D0018Intramural EPA EPA999999
6 · The paper itself

Abstract

The COVID-19 pandemic has raised interest in using devices that generate ultraviolet C (UVC) radiation as an alternative approach for reducing or eliminating microorganisms on surfaces. Studies investigating the efficacy of UVC radiation against pathogens use a wide range of laboratory methods and experimental conditions that can make cross-comparison of results and extrapolation of findings to real-world settings difficult. Here, we use three different UVC-generating sources - a broad-spectrum pulsed xenon light, a continuous light-emitting diode (LED), and a low-pressure mercury vapour lamp - to evaluate the impact of different experimental conditions on UVC efficacy against the coliphage MS2 on surfaces. We find that a nonlinear dose-response relationship exists for all three light sources, meaning that linear extrapolation of doses resulting in a 1-log

Indexed as

COVID-19MercuryDisinfectionHumansLevivirusPandemicsUltraviolet RaysXenonMercuryXenonLEDmercury lampMS2pulsed xenonsurface disinfectionultraviolet-CUVC

Identifiers

PMID35704393
PMCPMC9764853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.